Citations (309)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (29)
Sam G. Moreton, Andrew F. A. Arena, Yolanda Foy & Rachel E. Menzies. (2023) Reduced death anxiety as a mediator of the relationship between acute subjective effects of psychedelics and improved subjective well-being. Death Studies 47:10, pages 1115-1126.
Read now
Read now
Nicolas G. Glynos, Daniel J. Kruger, Nicholas Kolbman, Kevin Boehnke & Philippe Lucas. (2023) The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada. Journal of Psychoactive Drugs 55:5, pages 660-671.
Read now
Read now
Daniel J. Kruger, Julie Barron, Moss Herberholz & Kevin F. Boehnke. (2023) Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics. Journal of Psychoactive Drugs 55:5, pages 650-659.
Read now
Read now
B. Romeo, B. Fauvel, S. Dejean, L. Strika, A. Amirouche, V. Verroust, P. Piolino & A. Benyamina. (2023) Impact of a Naturalistic Psychedelic Experience on Smoking: A Retrospective Survey. Journal of Psychoactive Drugs 55:5, pages 640-649.
Read now
Read now
Raman Sharma, Rachel Batchelor & Jacqueline Sin. (2023) Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review. Journal of Psychoactive Drugs 55:5, pages 612-630.
Read now
Read now
Zofia Kozak, Matthew W. Johnson & Scott T. Aaronson. (2023) Assessing potential of psilocybin for depressive disorders. Expert Opinion on Investigational Drugs 32:10, pages 887-900.
Read now
Read now
Alan Kooi Davis, Yitong Xin, Nathan Sepeda & Lynnette A. Averill. (2023) Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. The American Journal of Drug and Alcohol Abuse 49:5, pages 587-596.
Read now
Read now
Nicolas G. Glynos, Christopher W. Fields, Julie Barron, Moss Herberholz, Daniel J. Kruger & Kevin F. Boehnke. (2023) Naturalistic Psychedelic Use: A World Apart from Clinical Care. Journal of Psychoactive Drugs 55:4, pages 379-388.
Read now
Read now
Baptiste Fauvel, Samuli Kangaslampi, Lana Strika-Bruneau, Bruno Roméo & Pascale Piolino. (2023) Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users. Journal of Psychoactive Drugs 55:2, pages 170-179.
Read now
Read now
Marc Galanter, William L. White, Jag Khalsa & Helena Hansen. (2023) A scoping review of spirituality in relation to substance use disorders: Psychological, biological, and cultural issues. Journal of Addictive Diseases 0:0, pages 1-9.
Read now
Read now
Hector Vargas-Perez, Taryn Elizabeth Grieder & Derek van der Kooy. (2023) Neural Plasticity in the Ventral Tegmental Area, Aversive Motivation during Drug Withdrawal and Hallucinogenic Therapy. Journal of Psychoactive Drugs 55:1, pages 62-72.
Read now
Read now
Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais, Paulo Cesar Ribeiro Barbosa & Lucas Oliveira Maia. (2022) Psychosocial and Drug Use Assessment of Regular vs. Non-Regular Ayahuasca Users in a Brazilian Sample: a Web-Based Survey . Substance Use & Misuse 57:7, pages 1072-1081.
Read now
Read now
Jan van Amsterdam & Wim van den Brink. (2022) The therapeutic potential of psilocybin: a systematic review. Expert Opinion on Drug Safety 21:6, pages 833-840.
Read now
Read now
David J. Cox, Albert Garcia-Romeu & Matthew W. Johnson. (2021) Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives. The American Journal of Drug and Alcohol Abuse 47:4, pages 444-454.
Read now
Read now
Joshua Falcon. (2021) Designing Consciousness: Psychedelics as Ontological Design Tools for Decolonizing Consciousness. Design and Culture 13:2, pages 143-163.
Read now
Read now
Joshua Falcon. (2021) Consciousness as a domain of extraterritoriality. Culture, Theory and Critique 62:1-2, pages 56-75.
Read now
Read now
Joel Bornemann. (2020) The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review. Journal of Psychoactive Drugs 52:4, pages 300-308.
Read now
Read now
James W. Hopper. (2020) Values and visions for the field of psychological trauma, from brain to re-moralization and social transformation. Journal of Trauma & Dissociation 21:3, pages 279-292.
Read now
Read now
Michael D. McGee. (2020) Awakening and Recovery. Alcoholism Treatment Quarterly 38:2, pages 266-285.
Read now
Read now
Shannon Mountain-Ray, Claire Simeone, Scott E. Hadland, Deborah S. Finnell, Rebecca Northup & Doreen MacLane-Baeder. (2019) Challenges and new horizons in substance use and addictions: Overview of the 2019 conference of the Association of Multidisciplinary Education and Research in Substance use and Addiction (AMERSA). Substance Abuse 40:4, pages 389-391.
Read now
Read now
Natasha L. Mason, Elisabeth Mischler, Malin V. Uthaug & Kim P. C. Kuypers. (2019) Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. Journal of Psychoactive Drugs 51:2, pages 123-134.
Read now
Read now
Caroline Dorsen, Joseph Palamar & Michele G. Shedlin. (2019) Ceremonial ‘Plant Medicine’ use and its relationship to recreational drug use: an exploratory study. Addiction Research & Theory 27:2, pages 68-75.
Read now
Read now
Stephen Bright & Martin Williams. (2018) Should Australian Psychology Consider Enhancing Psychotherapeutic Interventions with Psychedelic Drugs? A Call for Research. Australian Psychologist 53:6, pages 467-476.
Read now
Read now
David A. Pittaway. (2018) “To learn healing knowledge”: Philosophy, psychedelic studies and transformation. South African Journal of Philosophy 37:4, pages 438-451.
Read now
Read now
Matthew W. Johnson. (2018) Psychiatry might need some psychedelic therapy. International Review of Psychiatry 30:4, pages 285-290.
Read now
Read now
Albert Garcia-Romeu & William A. Richards. (2018) Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. International Review of Psychiatry 30:4, pages 291-316.
Read now
Read now
Peter S. Hendricks. (2018) Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry 30:4, pages 331-342.
Read now
Read now
Kelan Thomas, Benjamin Malcolm & Dan Lastra. (2017) Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. Journal of Psychoactive Drugs 49:5, pages 446-455.
Read now
Read now
David Erritzoe & William A. Richards. (2017) Lessons to be learned from early psychedelic therapy in Denmark. Nordic Journal of Psychiatry 71:7, pages 487-488.
Read now
Read now
Articles from other publishers (280)
Edward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller, David Nutt & Meg J. Spriggs. (2023) When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research. Neuroethics 17:1.
Crossref
Crossref
Boris D. Heifets & David E. Olson. (2023) Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology 49:1, pages 104-118.
Crossref
Crossref
Jennifer M. Mitchell & Brian T. Anderson. (2023) Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism. Neuropsychopharmacology 49:1, pages 96-103.
Crossref
Crossref
F.F. Youssef. 2024. Pharmacognosy. Pharmacognosy
397
407
.
Elliot Marseille, Christopher S. Stauffer, Manish Agrawal, Paul Thambi, Kimberly Roddy, Michael Mithoefer, Stefano M. Bertozzi & James G. Kahn. (2023) Group psychedelic therapy: empirical estimates of cost-savings and improved access. Frontiers in Psychiatry 14.
Crossref
Crossref
Christopher R. Nicholas, David M. HortonJulia MalickiAmelia BaltesPaul R. HutsonRandall T. Brown. (2023) Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings. Psychedelic Medicine.
Crossref
Crossref
Daniel Villiger & Manuel Trachsel. (2023) With great power comes great vulnerability: an ethical analysis of psychedelics’ therapeutic mechanisms proposed by the REBUS hypothesis. Journal of Medical Ethics 49:12, pages 826-832.
Crossref
Crossref
Natasha Biscoe, Amanda Bonson, Max Slavin, Walter Busuttil, Deirdre MacManus, Andrew Cox & Dominic Murphy. (2023) Psilocybin-assisted psychotherapy for the treatment of PTSD in UK armed forces veterans: A feasibility study protocol. European Journal of Trauma & Dissociation 7:4, pages 100359.
Crossref
Crossref
Paweł Holas & Justyna Kamińska. (2023) Mindfulness meditation and psychedelics: potential synergies and commonalities. Pharmacological Reports 75:6, pages 1398-1409.
Crossref
Crossref
Adam Wojtas. (2023) The possible place for psychedelics in pharmacotherapy of mental disorders. Pharmacological Reports 75:6, pages 1313-1325.
Crossref
Crossref
Niloufar Pouyan, Farnaz Younesi Sisi, Alireza Kargar, Milan Scheidegger, Roger S. McIntyre & Jonathan D. Morrow. (2023) The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review. CNS Drugs 37:12, pages 1027-1063.
Crossref
Crossref
Ewen Kervadec, Baptiste Fauvel, Lana Strika-Bruneau, Ammar Amirouche, Vincent Verroust, Pascale Piolino, Bruno Romeo & Amine Benyamina. (2023) Reduction of alcohol use and increase in psychological flexibility after a naturalistic psychedelic experience: a retrospective survey. Alcohol and Alcoholism.
Crossref
Crossref
Lindsay P. Cameron, Joseph Benetatos, Vern Lewis, Emma M. Bonniwell, Alaina M. Jaster, Rafael Moliner, Eero Castrén, John D. McCorvy, Mikael Palner & Argel Aguilar-Valles. (2023)
Beyond the 5-HT
2A
Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action
. The Journal of Neuroscience 43:45, pages 7472-7482.
Crossref
Crossref
David B. Yaden, Andrea P. Berghella, Peter S. Hendricks, Mary E. Yaden, Michael Levine, Julia Rohde, Sandeep Nayak, Matthew W. Johnson & Albert Garcia-Romeu. (2023) IUPHAR-review: The Integration of Classic Psychedelics into Current Substance Use Disorder Treatment Models. Pharmacological Research, pages 106998.
Crossref
Crossref
Mark A. Geyer. (2023) A brief historical overview of psychedelic research. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.
Crossref
Crossref
Amanda E. Downey, Maxine Boyd, Anita V. Chaphekar, Joshua Woolley & Marissa Raymond‐Flesch. (2023) “But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin‐assisted psychotherapy. International Journal of Eating Disorders 56:11, pages 2142-2148.
Crossref
Crossref
Dana Kaminski & Justin P. Reinert. (2023) The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review. Annals of Pharmacotherapy.
Crossref
Crossref
Blerida Banushi & Vince Polito. (2023) A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics. Biology 12:11, pages 1380.
Crossref
Crossref
Abigail Calder, Seline Mock, Nicole Friedli, Patrick Pasi & Gregor Hasler. (2023) Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms. European Neuropsychopharmacology 75, pages 1-14.
Crossref
Crossref
Han-Bing Song & Tolgor Bau. (2023) Conocybe Section Pilosellae in China: Reconciliation of Taxonomy and Phylogeny Reveals Seven New Species and a New Record. Journal of Fungi 9:9, pages 924.
Crossref
Crossref
Kengo Yonezawa, Hideaki Tani, Shinichiro Nakajima & Hiroyuki Uchida. (2023) Development of the Japanese version of the 30‐item Mystical Experience Questionnaire. Neuropsychopharmacology Reports.
Crossref
Crossref
Anna Ross & Jake Hawthorn. (2023) The Use of Illicit Drugs in Therapy: an Introduction. Current Addiction Reports 10:4, pages 817-824.
Crossref
Crossref
Marc J. Weintraub, Jessica K. JeffreyCharles S. GrobMegan C. IchinoseR. Lindsey BergmanZiva D. CooperDavid J. Miklowitz. (2023) Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development. Psychedelic Medicine.
Crossref
Crossref
Pravesh Sharma, Quang Anh Nguyen, Sadie J Matthews, Erin Carpenter, Douglas B Mathews, Christi A Patten & Christopher J Hammond. (2023) Psilocybin history, action and reaction: A narrative clinical review. Journal of Psychopharmacology 37:9, pages 849-865.
Crossref
Crossref
Omar B. Sanchez-Reyes, Gregory Zilberg, John D. McCorvy & Daniel Wacker. (2023) Molecular insights into GPCR mechanisms for drugs of abuse. Journal of Biological Chemistry 299:9, pages 105176.
Crossref
Crossref
Nuno Azevedo, Miguel Oliveira Da Silva & Luís Madeira. (2023) Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges. Philosophies 8:5, pages 76.
Crossref
Crossref
Mary G. Hornick & Ashley Stefanski. (2023) Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder. Frontiers in Pharmacology 14.
Crossref
Crossref
Philip Kamilar-Britt, Elana B. GordisMitch Earleywine. (2023) The Therapeutic Alliance in Psychedelic-Assisted Psychotherapy: A Novel Target for Research and Interventions. Psychedelic Medicine.
Crossref
Crossref
Zachary Herrmann, Adam W. Levin, Steven P. ColeSarah SlabaughBrian Barnett, Andrew Penn, Rakesh JainCharles RaisonBhavya RajannaSaundra Jain. (2023) Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States. Psychedelic Medicine.
Crossref
Crossref
Kevin F. Boehnke, Kasey Cox, Cody Weston, Moss Herberholz, Nicolas Glynos, Nicholas Kolbman, Christopher W. Fields, Julie Barron & Daniel J. Kruger. (2023) Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers. Frontiers in Psychiatry 14.
Crossref
Crossref
Gregory S. BarberCharles C. Dike. (2023) Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry. Psychiatric Services 74:8, pages 838-846.
Crossref
Crossref
Stephanie Karzon AbramsBrenden Samuel RabinovitchRayyan ZafarAly Shah AzizNicholas Paul CherupDavid W. McMillanJessica L. NielsonEvan Cole Lewis. (2023) Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics. Neurotrauma Reports 4:1, pages 543-550.
Crossref
Crossref
Stephanie Knatz Peck, Samantha Shao, Tessa Gruen, Kevin Yang, Alexandra Babakanian, Julie Trim, Daphna M. Finn & Walter H. Kaye. (2023) Psilocybin therapy for females with anorexia nervosa: a phase 1, open-label feasibility study. Nature Medicine 29:8, pages 1947-1953.
Crossref
Crossref
Silvia J. Franco Corso, Kate Y. O'Malley, Saleena Subaiya, Danielle Mayall & Elias Dakwar. (2023) The role of non-ordinary states of consciousness occasioned by mind-body practices in mental health illness. Journal of Affective Disorders 335, pages 166-176.
Crossref
Crossref
Martin Steinberg, Paul Rosenberg & Albert Garcia-Romeu. (2023) The Potential for Psychedelics to Improve Coping Skills and Resilience in Persons With Newly Diagnosed Mild Cognitive Impairment or Early Alzheimer’s Disease. Current Geriatrics Reports 12:3, pages 149-155.
Crossref
Crossref
Robert B. Kargbo. (2023) Microbiome: The Next Frontier in Psychedelic Renaissance. Journal of Xenobiotics 13:3, pages 386-401.
Crossref
Crossref
Guy M. GoodwinEkaterina MalievskaiaGregory A. FonzoCharles B. Nemeroff. (2023) Must Psilocybin Always “Assist Psychotherapy”?. American Journal of Psychiatry.
Crossref
Crossref
Nicholas A. Carlisle, Haley Maria DourronSarah MacCarthyAli John ZarrabiPeter S. Hendricks. (2023) Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults. Psychedelic Medicine.
Crossref
Crossref
Rabeet Tariq. (2023) Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and
Potential Harms. Current Reviews in Clinical and Experimental Pharmacology 18:2, pages 94-109.
Crossref
Crossref
Justin N Bonnieux, Baeleigh VanderZwaag, Zahra Premji, Albert Garcia-Romeu & Mauricio A Garcia-Barrera. (2023) Psilocybin’s effects on cognition and creativity: A scoping review. Journal of Psychopharmacology 37:7, pages 635-648.
Crossref
Crossref
Patrick Fissler, Anja Vandersmissen, Marco Filippi, Rezan Nehir Mavioglu, Felix Scholkmann, Alexander Karabatsiakis & Rainer Krähenmann. (2023) Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies. Journal of Psychopharmacology 37:7, pages 679-686.
Crossref
Crossref
Emma I Kopra, Jason A Ferris, Adam R Winstock, Kim PC Kuypers, Allan H Young & James J Rucker. (2023) Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020. Journal of Psychopharmacology 37:7, pages 733-748.
Crossref
Crossref
Allison Feduccia, Gabby Agin-Liebes, Collin M. Price, Nicole Grinsell, Summer Paradise & David M. Rabin. (2023) The need for establishing best practices and gold standards in psychedelic medicine. Journal of Affective Disorders 332, pages 47-54.
Crossref
Crossref
Ali Asghar Hakami Zanjani, Teresa Quynh Tram Nguyen, Luise Jacobsen & Himanshu Khandelia. (2023) The molecular basis of the antidepressant action of the magic mushroom extract, psilocin. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1871:4, pages 140914.
Crossref
Crossref
Winston De La Haye, Geoffrey Walcott, Jordan Eaton, Jhoelle Beckford & Janelle Greene. (2023) Psychedelic Assisted Psychotherapy preparing your target using psychohistoriography: a Jamaican perspective. Frontiers in Psychiatry 14.
Crossref
Crossref
Rayyan Zafar, Maxim Siegel, Rebecca Harding, Tommaso Barba, Claudio Agnorelli, Shayam Suseelan, Leor Roseman, Matthew Wall, David John Nutt & David Erritzoe. (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Frontiers in Psychiatry 14.
Crossref
Crossref
Lilith Becher, Federico Nanni & Michael Koslowski. (2023) Psychedelikagestützte Psychotherapie in der Behandlung depressiver Störungen. Nervenheilkunde 42:07/08, pages 450-458.
Crossref
Crossref
Michaela Barber, John Gardner & Adrian Carter. (2023) Transformative agents of change and investigative neurotechnologies: A qualitative study of psychedelic technology identities. SSM - Qualitative Research in Health 3, pages 100202.
Crossref
Crossref
Lana Strika-Bruneau, Baptiste Fauvel, David Dupuis & Amine Benyamina. (2023) Articulation de la thérapie d’acceptation et d’engagement à la psychothérapie assistée par psychédéliques en addictologie. L'Évolution Psychiatrique 88:2, pages 284-298.
Crossref
Crossref
Mark A. Mattaini, Kathryn M. Roose & Stephen B. Fawcett. (2022) Behavioral Interventions Contributing to Reducing Poverty and Inequities. Behavior and Social Issues 32:1, pages 314-337.
Crossref
Crossref
Scott Hoener, Aaron Wolfgang, David Nissan & Edmund Howe. (2023) Ethical considerations for psychedelic-assisted therapy in military clinical settings. Journal of Medical Ethics, pages jme-2023-108943.
Crossref
Crossref
Edward Jacobs. (2023) Transformative experience and informed consent to psychedelic-assisted psychotherapy. Frontiers in Psychology 14.
Crossref
Crossref
Kevin F. Boehnke, Daniel J. Kruger & Philippe Lucas. (2023) Changed Substance Use After Psychedelic Experiences Among Individuals in Canada. International Journal of Mental Health and Addiction.
Crossref
Crossref
Noah D. Gold, Austin J. MallardJacob C. HermannRichard J. ZeifmanBroc A. PagniMichael P. BogenschutzStephen Ross. (2023) Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis. Journal of Palliative Medicine.
Crossref
Crossref
S. B. Thal, M. Wieberneit, J. M. Sharbanee, P. M. Skeffington, R. Bruno, T. Wenge & S. J. Bright. (2023) Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review. Journal of Humanistic Psychology.
Crossref
Crossref
Alan K Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong & Rafaelle L Lancelotta. (2023) Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD. BMJ Open 13:5, pages e068884.
Crossref
Crossref
Jennifer L. Jones. (2023) Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users. Frontiers in Psychiatry 14.
Crossref
Crossref
D. P. Effinger, S. G. Quadir, M. C. Ramage, M. G. Cone & M. A. Herman. (2023) Sex-specific effects of psychedelic drug exposure on central amygdala reactivity and behavioral responding. Translational Psychiatry 13:1.
Crossref
Crossref
Sidath Rankaduwa & Adrian M Owen. (2023) Psychedelics, entropic brain theory, and the taxonomy of conscious states: a summary of debates and perspectives. Neuroscience of Consciousness 2023:1.
Crossref
Crossref
Bryan McCarthy. (2023) Christianity and Psychedelic Medicine: A Pastoral Approach. Christian bioethics: Non-Ecumenical Studies in Medical Morality 29:1, pages 31-57.
Crossref
Crossref
Daniel Meling & Milan Scheidegger. (2023) Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective. Frontiers in Psychology 14.
Crossref
Crossref
Daniel F. Kelly, Keith Heinzerling, Akanksha Sharma, Shanthi Gowrinathan, Karina Sergi & Regin Jay Mallari. (2023) Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery 92:4, pages 680-694.
Crossref
Crossref
Matthew Lyes, Kevin H. Yang, Joel Castellanos & Timothy Furnish. (2023) Microdosing psilocybin for chronic pain: a case series. Pain 164:4, pages 698-702.
Crossref
Crossref
Jonathan Brett, Elizabeth Knock, P. Todd Korthuis, Paul Liknaitzky, Kevin S. Murnane, Christopher R. Nicholas, James C. PattersonIIII & Christopher S. Stauffer. (2023) Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder. Frontiers in Psychiatry 14.
Crossref
Crossref
Florence Butlen-Ducuing, Drummond E-Wen McCulloch, Marion Haberkamp, Taina Mattila, Ewa Bałkowiec-Iskra, Georgios Aislaitner, Pavel Balabanov, Johan Lundberg, Dea Siggaard Stenbæk, Andre Elferink, Gitte M Knudsen & Steffen Thirstrup. (2023) The therapeutic potential of psychedelics: the European regulatory perspective. The Lancet 401:10378, pages 714-716.
Crossref
Crossref
Pim B. van der Meer, Juan J. Fuentes, Ad A. Kaptein, Jan W. Schoones, Marleen M. de Waal, Anneke E. Goudriaan, Kees Kramers, Arnt Schellekens, Metten Somers, Matthijs G. Bossong & Albert Batalla. (2023) Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in Psychiatry 14.
Crossref
Crossref
Andrea Mastinu, Margrate Anyanwu, Marinella Carone, Giulia Abate, Sara Anna Bonini, Gregorio Peron, Emanuela Tirelli, Mariachiara Pucci, Giovanni Ribaudo, Erika Oselladore, Marika Premoli, Alessandra Gianoncelli, Daniela Letizia Uberti & Maurizio Memo. (2023) The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. International Journal of Molecular Sciences 24:2, pages 1329.
Crossref
Crossref
Kenneth Alper, Janelle Cange, Ria Sah, Deanna Schreiber-Gregory, Henry Sershen & K. Yaragudri Vinod. (2023) Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice. Frontiers in Pharmacology 13.
Crossref
Crossref
Miriam Marguilho, Inês Figueiredo & Pedro Castro-Rodrigues. (2022) A unified model of ketamine’s dissociative and psychedelic properties. Journal of Psychopharmacology 37:1, pages 14-32.
Crossref
Crossref
Abigail E. Calder & Gregor Hasler. (2022) Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology 48:1, pages 104-112.
Crossref
Crossref
Sabrina Correa da Costa, Yara Moustafa, Adriana Vasquez & Teresa Rummans. 2023. Reference Module in Neuroscience and Biobehavioral Psychology. Reference Module in Neuroscience and Biobehavioral Psychology.
Adam L. Halberstadt, Dino Luethi, Marius C. Hoener, Daniel Trachsel, Simon D. Brandt & Matthias E. Liechti. (2022) Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. Psychopharmacology 240:1, pages 115-126.
Crossref
Crossref
Shannon Kim, Rishi M. Nadar, Jack DeRuiter, Suhrud Pathak, Sindhu Ramesh, Timothy Moore, Dinesh Chandra Agrawal & Muralikrishnan Dhanasekaran. 2023. Mushrooms with Therapeutic Potentials. Mushrooms with Therapeutic Potentials
369
392
.
Chris MeyersChris Meyers. 2023. Drug Legalization. Drug Legalization
25
52
.
Emmanuelle A. D. SchindlerDeepak Cyril D’Souza. (2022) The therapeutic potential of psychedelics. Science 378:6624, pages 1051-1053.
Crossref
Crossref
Elliot Marseille, Stefano Bertozzi & James G. Kahn. (2022) The economics of psychedelic-assisted therapies: A research agenda. Frontiers in Psychiatry 13.
Crossref
Crossref
Victor Mocanu, Lindsay Mackay, Devon Christie & Elena Argento. (2022) Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy. Substance Abuse Treatment, Prevention, and Policy 17:1.
Crossref
Crossref
Ana María Ortiz Bernal, Charles L. Raison, Rafael L. Lancelotta & Alan K. Davis. (2022) Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Frontiers in Psychiatry 13.
Crossref
Crossref
Logan Neitzke-Spruill. (2022) Psychedelics and Desistance From Crime: Lessons From the Concord Prison Experiment. Journal of Humanistic Psychology, pages 002216782211362.
Crossref
Crossref
Sascha B Thal, Michelle Wieberneit, Jason M Sharbanee, Petra M Skeffington, Paris Baker, Raimondo Bruno, Tobias Wenge & Stephen J Bright. (2022) Therapeutic (Sub)stance: Current practice and therapeutic conduct in preparatory sessions in substance-assisted psychotherapy—A systematized review. Journal of Psychopharmacology 36:11, pages 1191-1207.
Crossref
Crossref
Hamna Raheel, Unaiza Naeem, Asim Shaikh & Omer Ahmed Shaikh. (2022) The psychedelic renaissance: can psilocybin possibly combat depression?. International Journal of Surgery: Global Health 5:6, pages e89-e89.
Crossref
Crossref
Alex C. Kwan, David E. Olson, Katrin H. Preller & Bryan L. Roth. (2022) The neural basis of psychedelic action. Nature Neuroscience 25:11, pages 1407-1419.
Crossref
Crossref
Alejandra Ellison-Barnes & Panagis Galiatsatos. (2022) Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. Medical Clinics of North America 106:6, pages 1067-1080.
Crossref
Crossref
Milena Bryła. (2022) What Conceptual Metaphors Appear in Texts on Psychedelics and Medicine? Corpus-Based Cognitive Study. Respectus Philologicus 42:47, pages 154-166.
Crossref
Crossref
Anna Søndergaard, Martin Korsbak Madsen, Brice Ozenne, Sophia Armand, Gitte Moos Knudsen, Patrick MacDonald Fisher & Dea Siggaard Stenbæk. (2022) Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals. Frontiers in Psychology 13.
Crossref
Crossref
Phoebe Friesen. (2022) Psychosis and psychedelics: Historical entanglements and contemporary contrasts. Transcultural Psychiatry 59:5, pages 592-609.
Crossref
Crossref
Natalie Gukasyan & Sandeep M. Nayak. (2021) Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy. Transcultural Psychiatry 59:5, pages 652-664.
Crossref
Crossref
Josephine Cruzat, Yonatan Sanz Perl, Anira Escrichs, Jakub Vohryzek, Christopher Timmermann, Leor Roseman, Andrea I. Luppi, Agustin Ibañez, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi, Gustavo Deco & Morten L. Kringelbach. (2022) Effects of classic psychedelic drugs on turbulent signatures in brain dynamics. Network Neuroscience 6:4, pages 1104-1124.
Crossref
Crossref
Anna U. Odland, Jesper L. Kristensen & Jesper T. Andreasen. (2022) Animal Behavior in Psychedelic Research. Pharmacological Reviews 74:4, pages 1176-1205.
Crossref
Crossref
Matthias Forstmann & Christina Sagioglou. (2022) New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances. European Psychologist 27:4, pages 291-301.
Crossref
Crossref
I. Erkizia-Santamaría, R. Alles-Pascual, I. Horrillo, J.J. Meana & J.E. Ortega. (2022) Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomedicine & Pharmacotherapy 154, pages 113612.
Crossref
Crossref
Niloufar Pouyan, Zahra Halvaei Khankahdani, Farnaz Younesi Sisi, Yena Lee, Joshua D. Rosenblat, Kayla M. Teopiz, Leanna M. W. Lui, Mehala Subramaniapillai, Kangguang Lin, Flora Nasri, Nelson Rodrigues, Hartej Gill, Orly Lipsitz, Bing Cao, Roger Ho, David Castle & Roger S. McIntyre. (2022) A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review. CNS Drugs 36:10, pages 1031-1047.
Crossref
Crossref
Damien Prouzeau, Ismaël Conejero, Peter L. Voyvodic, Carine Becamel, Mocrane Abbar & Jorge Lopez-Castroman. (2022) Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. Current Psychiatry Reports 24:10, pages 573-581.
Crossref
Crossref
James Bailey Sanford. (2022) Psychedelics hold promise for primary care research. Family Practice 39:5, pages 992-993.
Crossref
Crossref
Ada Kałużna, Marco Schlosser, Emily Gulliksen Craste, Jack Stroud & James Cooke. (2022) Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. Journal of Psychedelic Studies 6:2, pages 111-136.
Crossref
Crossref
Holly Crisp & Glen O. GabbardSeamus Bhatt-Mackin, Amanda McEpplan, Keith Dobson, Ph.D.Jean Cottraux. 2022. Gabbard’s Textbook of Psychotherapeutic Treatments. Gabbard’s Textbook of Psychotherapeutic Treatments.
Holly Crisp & Glen O. Gabbard. 2022. Gabbard’s Textbook of Psychotherapeutic Treatments. Gabbard’s Textbook of Psychotherapeutic Treatments.
Brian S. Barnett & Jeremy Weleff. (2022) Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 52:9, pages 365-370.
Crossref
Crossref
Kaitlin R. McManus, Regan Patrick, Meg I. Striepe, Mia J. Drury, Rosain Ozonsi, Brent P. Forester & Marc S. Weinberg. (2022) Psychedelics for Alzheimer's Disease Palliative Care. Advances in Psychiatry and Behavioral Health 2:1, pages 37-46.
Crossref
Crossref
D. Dias da Silva, A.M. Brito-da-Costa, S. Lemos Martins, R.J. Dinis-Oliveira & A. Madureira-Carvalho. (2022) P03-21 Magic mushrooms and psilocybin: pharmacokinetics, pharmacodynamics, and clinical applications. Toxicology Letters 368, pages S97.
Crossref
Crossref
Paul J. Fletcher, Zhaoxia Li, Xiaodong Ji, Guy A. Higgins, Douglas Funk & A.D. Lê. (2022) Effects of pimavanserin and lorcaserin on alcohol self-administration and reinstatement in male and female rats. Neuropharmacology 215, pages 109150.
Crossref
Crossref
Michiel van Elk & David Bryce Yaden. (2022) Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. Neuroscience & Biobehavioral Reviews 140, pages 104793.
Crossref
Crossref
Sabrina Correa da Costa, Tyler Oesterle, Teresa A. Rummans, Elliot Richelson & Mark Gold. (2022) Psychedelic drugs for psychiatric disorders. Journal of the Neurological Sciences 440, pages 120332.
Crossref
Crossref
Fúlvio Rieli Mendes, Cristiane dos Santos Costa, Victor Distefano Wiltenburg, Gabriela Morales-Lima, João Ariel Bonar Fernandes & Renato Filev. (2022) Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 3, pages 100025.
Crossref
Crossref
Sen Yao, Chuanzheng Wei, Hui Lin, Peng Zhang, Yuanyuan Liu, Youjin Deng, Qianhui Huang & Baogui Xie. (2022) Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways. Journal of Fungi 8:8, pages 870.
Crossref
Crossref
Nicole Fadahunsi, Jens Lund, Alberte Wollesen Breum, Cecilie Vad Mathiesen, Isabella Beck Larsen, Gitte Moos Knudsen, Anders Bue Klein & Christoffer Clemmensen. (2022) Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice. Translational Psychiatry 12:1.
Crossref
Crossref
Mitch Earleywine & Zachary M. Herrmann. (2022) Psychedelics for Psychiatric Disorders: Promise, Not Panacea. Psychiatric Annals 52:9, pages 354-358.
Crossref
Crossref
Peter Selby & Laurie Zawertailo. (2022) Tobacco Addiction. New England Journal of Medicine 387:4, pages 345-354.
Crossref
Crossref
Kwonmok Ko, Gemma Knight, James J. Rucker & Anthony J. Cleare. (2022) Psychedelics, Mystical Experience, and Therapeutic Efficacy: A Systematic Review. Frontiers in Psychiatry 13.
Crossref
Crossref
Seetal Dodd, Trevor R. Norman, Harris A. Eyre, Stephen M. Stahl, Arnie Phillips, André F. Carvalho & Michael Berk. (2022) Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy. CNS Spectrums, pages 1-11.
Crossref
Crossref
Dina Fradkin. (2021) Psilocybin: A brief overview for psychiatric mental health nurse practitioners. Perspectives in Psychiatric Care 58:3, pages 1200-1203.
Crossref
Crossref
Drummond E-Wen McCulloch, Gitte Moos Knudsen, Frederick Streeter Barrett, Manoj K. Doss, Robin Lester Carhart-Harris, Fernando E. Rosas, Gustavo Deco, Morten L. Kringelbach, Katrin H. Preller, Johannes G. Ramaekers, Natasha L. Mason, Felix Müller & Patrick MacDonald Fisher. (2022) Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neuroscience & Biobehavioral Reviews 138, pages 104689.
Crossref
Crossref
V. L. Matrenitsky. (2022) РЕНЕСАНС ПСИХОДЕЛІЧНОЇ ТЕРАПІЇ ТА ЇЇ ЗНАЧЕННЯ ДЛЯ УКРАЇНИ. Likarska sprava:3-4, pages 37-59.
Crossref
Crossref
Snehal R. Bhatt, Maya Armstrong, Tassy Parker, Marcello Maviglia, Rebecca Kass, Lawrence Leeman, Paul Romo & Douglas Ziedonis. (2022) Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Frontiers in Pharmacology 13.
Crossref
Crossref
Sam Gandy. (2022) Predictors and potentiators of psychedelic-occasioned mystical experiences. Journal of Psychedelic Studies 6:1, pages 31-47.
Crossref
Crossref
Mark Kang, Lindsay Mackay, Devon Christie, Cody Callon & Elena Argento. (2022) Can psychedelic-assisted psychotherapy play a role in enhancing motivation to change in addiction treatment settings?. Journal of Psychedelic Studies 6:1, pages 5-9.
Crossref
Crossref
Grant Jones, Joshua Lipson & Matthew K. Nock. (2022) Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Scientific Reports 12:1.
Crossref
Crossref
Lyons Blum. (2022) Magic Mushrooms and Their Medicinal Use. Ellipsis: A Journal of Art, Ideas, and Literature 47.
Crossref
Crossref
Mauro Cavarra, Alessandra Falzone, Johannes G. Ramaekers, Kim P. C. Kuypers & Carmela Mento. (2022) Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions. Frontiers in Psychology 13.
Crossref
Crossref
Teresa Reynolds Sousa, João Rema, Sergio Machado & Filipa Novais. (2022) Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological
Targets. Current Topics in Medicinal Chemistry 22:15, pages 1250-1260.
Crossref
Crossref
Elena Argento, Shira Goldenberg, Kathleen Deering, Jennifer Lavalley, Melissa Braschel, Brittany Bingham & Kate Shannon. (2022) Interest in receiving psychedelic-assisted therapy among marginalized women: Implications and findings from a community-based study in Canada. Drug and Alcohol Dependence Reports 3, pages 100044.
Crossref
Crossref
H. T. McGovern, P. Leptourgos, B. T. Hutchinson & P. R. Corlett. (2022) Do psychedelics change beliefs?. Psychopharmacology 239:6, pages 1809-1821.
Crossref
Crossref
Alaina M. Jaster, Harrison Elder, Samuel A. Marsh, Mario de la Fuente Revenga, S. Stevens Negus & Javier González-Maeso. (2022) Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents. Psychopharmacology 239:6, pages 1665-1677.
Crossref
Crossref
Dimitri Daldegan-Bueno, Lucas Oliveira Maia, Carolina Marcolino Massarentti & Luís Fernando Tófoli. (2022) Ayahuasca and tobacco smoking cessation: results from an online survey in Brazil. Psychopharmacology 239:6, pages 1767-1782.
Crossref
Crossref
David Bender & David J. Hellerstein. (2022) Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology 239:6, pages 1907-1932.
Crossref
Crossref
R.C. Van Court, M.S. Wiseman, K.W. Meyer, D.J. Ballhorn, K.R. Amses, J.C. Slot, B.T.M. Dentinger, R. Garibay-Orijel & J.K. Uehling. (2022) Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development. Fungal Biology 126:4, pages 308-319.
Crossref
Crossref
Shevaugn Johnson & Quentin C. Black. (2020) Classic Psychedelics as a Psychotherapeutic Aid in the Treatment of Stimulant Use Disorder: a Case Report. International Journal of Mental Health and Addiction 20:2, pages 744-753.
Crossref
Crossref
Wendy Pots & Farid Chakhssi. (2022) Psilocybin-Assisted Compassion Focused Therapy for Depression. Frontiers in Psychology 13.
Crossref
Crossref
Galen Ballentine, Samuel Freesun Friedman & Danilo Bzdok. (2022) Trips and neurotransmitters: Discovering principled patterns across 6850 hallucinogenic experiences. Science Advances 8:11.
Crossref
Crossref
Maria Bălăeţ. (2022) Psychedelic Cognition—The Unreached Frontier of Psychedelic Science. Frontiers in Neuroscience 16.
Crossref
Crossref
Elaine Meade, Sarah Hehir, Neil Rowan & Mary Garvey. (2022) Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain. Journal of Fungi 8:3, pages 290.
Crossref
Crossref
Drummond E-Wen McCulloch, Maria Zofia Grzywacz, Martin Korsbak Madsen, Peter Steen Jensen, Brice Ozenne, Sophia Armand, Gitte Moos Knudsen, Patrick MacDonald Fisher & Dea Siggaard Stenbæk. (2022) Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report. Frontiers in Pharmacology 13.
Crossref
Crossref
Max Wolff, Lea J Mertens, Marie Walter, Sören Enge & Ricarda Evens. (2022) The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs’ effects on psychological flexibility. Journal of Psychopharmacology 36:3, pages 387-408.
Crossref
Crossref
Anne K Schlag, Jacob Aday, Iram Salam, Jo C Neill & David J Nutt. (2022) Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology 36:3, pages 258-272.
Crossref
Crossref
Gerhard Gründer, Manuela Brand, Laura Kärtner, Dennis Scharf, Christian Schmitz, Moritz Spangemacher & Lea J. Mertens. (2022) Sind Psychedelika schnell wirksame Antidepressiva?Are psychedelics fast acting antidepressant agents?. Der Nervenarzt 93:3, pages 254-262.
Crossref
Crossref
Shawn Ziff, Benjamin Stern, Gregory Lewis, Maliha Majeed & Vasavi Rakesh Gorantla. (2022) Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus.
Crossref
Crossref
Malin Vedøy Uthaug, Natasha L Mason, Martha N Havenith, Michael Vancura & Johannes G Ramaekers. (2022) An experience with Holotropic Breathwork is associated with improvement in non-judgement and satisfaction with life while reducing symptoms of stress in a Czech-speaking population. Journal of Psychedelic Studies 5:3, pages 176-189.
Crossref
Crossref
Elena Argento, M. Eugenia Socias, Kanna Hayashi, JinCheol Choi, Lindsay Mackay, Devon Christie, M-J Milloy & Kora DeBeck. (2022) Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. International Journal of Drug Policy 100, pages 103518.
Crossref
Crossref
Zachary J. Kunicki, Mats Hallgren, Lisa A. Uebelacker, Richard A. Brown, Lawrence H. Price & Ana M. Abrantes. (2022) Examining the effect of exercise on the relationship between affect and cravings among smokers engaged in cessation treatment. Addictive Behaviors 125, pages 107156.
Crossref
Crossref
Athanasios Markopoulos, Antonio Inserra, Danilo De Gregorio & Gabriella Gobbi. (2022) Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder. Frontiers in Pharmacology 12.
Crossref
Crossref
Frederick S. Barrett, Yun Zhou, Theresa M. Carbonaro, Joshua M. Roberts, Gwenn S. Smith, Roland R. Griffiths & Dean F. Wong. (2022) Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. Frontiers in Neuroergonomics 2.
Crossref
Crossref
Pedro J Teixeira, Matthew W Johnson, Christopher Timmermann, Rosalind Watts, David Erritzoe, Hannah Douglass, Hannes Kettner & Robin L Carhart-Harris. (2021) Psychedelics and health behaviour change. Journal of Psychopharmacology 36:1, pages 12-19.
Crossref
Crossref
Daniel Perkins, Emerita S. Opaleye, Hana Simonova, José C. Bouso, Luís F. Tófoli, Nicole L. GalvÃo‐Coelho, Violeta Schubert & Jerome Sarris. (2021) Associations between ayahuasca consumption in naturalistic settings and current alcohol and drug use: Results of a large international cross‐sectional survey. Drug and Alcohol Review 41:1, pages 265-274.
Crossref
Crossref
Lea J. Mertens, Michael Koslowski, Felix Betzler, Ricarda Evens, Maria Gilles, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Andreas Ströhle, Max Wolff, Stefan Wellek & Gerhard Gründer. (2022) Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) – Rationale and study design. Neuroscience Applied 1, pages 100104.
Crossref
Crossref
Yu Kyung Lee, Mark S. Gold & Brian S. Fuehrlein. (2022) Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. Journal of the Neurological Sciences 432, pages 120094.
Crossref
Crossref
Justin C. Strickland & Matthew W. Johnson. 2022. Behavioral Pharmacology of Drug Abuse: Current Status. Behavioral Pharmacology of Drug Abuse: Current Status
105
132
.
Henrique M. Fernandes, Gustavo Deco & Morten L. Kringelbach. 2022. Connectomic Deep Brain Stimulation. Connectomic Deep Brain Stimulation
543
559
.
Joseph Dumit & Emilia Sanabria. 2022. The Palgrave Handbook of the Anthropology of Technology. The Palgrave Handbook of the Anthropology of Technology
291
308
.
P. V. Asharani & Mythily Subramaniam. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
775
800
.
Andreia Machado Brito-da-Costa, Diana Dias da Silva, Áurea Madureira-Carvalho & Ricardo Jorge Dinis-Oliveira. 2022. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
2427
2455
.
P. V. Asharani & Mythily Subramaniam. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
27
.
Andreia Machado Brito-da-Costa, Diana Dias-da-Silva, Áurea Madureira-Carvalho & Ricardo Jorge Dinis-Oliveira. 2021. Handbook of Substance Misuse and Addictions. Handbook of Substance Misuse and Addictions
1
29
.
Matthew W. Johnson. 2022. Disruptive Psychopharmacology. Disruptive Psychopharmacology
213
227
.
Halsey Niles, Colleen Fogg, Ben Kelmendi & Mark Lazenby. (2021) Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies. BMC Palliative Care 20:1.
Crossref
Crossref
David M. Horton, Blaise Morrison & Judy Schmidt. (2021) Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy. American Journal of Psychotherapy 74:4, pages 140-149.
Crossref
Crossref
William R Smith & Dominic Sisti. (2021) Ethics and ego dissolution: the case of psilocybin. Journal of Medical Ethics 47:12, pages 807-814.
Crossref
Crossref
David B. Yaden, Andrea P. Berghella, Paul S. Regier, Albert Garcia-Romeu, Matthew W. Johnson & Peter S. Hendricks. (2021) Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. International Journal of Drug Policy 98, pages 103380.
Crossref
Crossref
Michael Koslowski, Matthew W. Johnson, Gerhard Gründer & Felix Betzler. (2021) Novel Treatment Approaches for Substance Use Disorders: Therapeutic Use of Psychedelics and the Role of Psychotherapy. Current Addiction Reports 9:1, pages 48-58.
Crossref
Crossref
Julia Bornemann, James B. Close, Meg J. Spriggs, Robin Carhart-Harris & Leor Roseman. (2021) Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. Frontiers in Psychiatry 12.
Crossref
Crossref
Meg J. Spriggs, Hannah M. Douglass, Rebecca J. Park, Tim Read, Jennifer L. Danby, Frederico J. C. de Magalhães, Kirsty L. Alderton, Tim M. Williams, Allan Blemings, Adele Lafrance, Dasha E. Nicholls, David Erritzoe, David J. Nutt & Robin L. Carhart-Harris. (2021) Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”. Frontiers in Psychiatry 12.
Crossref
Crossref
Benjamin R. Lewis & Kevin Byrne. (2021) Is MDD the right target for early-stage psychedelic-assisted therapy trials?. Journal of Psychedelic Studies 5:2, pages 65-68.
Crossref
Crossref
Federico Cavanna, Carla Pallavicini, Virginia Milano, Juan Cuiule, Rocco Di Tella, Pablo González & Enzo Tagliazucchi. (2021) Lifetime use of psychedelics is associated with better mental health indicators during the COVID-19 pandemic. Journal of Psychedelic Studies 5:2, pages 83-93.
Crossref
Crossref
William M. Meil, William Farrell & Reem Satti. 2021. Addictions - Diagnosis and Treatment. Addictions - Diagnosis and Treatment.
Maggie K. Kiraga, Natasha L. Mason, Malin V. Uthaug, Kim I.M. van Oorsouw, Stefan W. Toennes, Johannes G. Ramaekers & Kim P. C. Kuypers. (2021) Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being. Frontiers in Pharmacology 12.
Crossref
Crossref
Riccardo Miceli McMillan. (2021) Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement. Journal of Medical Ethics 47:10, pages 701-705.
Crossref
Crossref
James B. Close, Julia Bornemann, Maria Piggin, Sandra Jayacodi, Lisa Xiaolu Luan, Robin Carhart-Harris & Meg Jo Spriggs. (2021) Co-design of Guidance for Patient and Public Involvement in Psychedelic Research. Frontiers in Psychiatry 12.
Crossref
Crossref
Elena Argento, Devon Christie, Lindsay Mackay, Cody Callon & Zach Walsh. (2021) Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems. Frontiers in Psychiatry 12.
Crossref
Crossref
Etienne Artru & Thomas Rabeyron. (2021) Psychédéliques, psychothérapie et symbolisation : une revue de littérature dans le champ de la dépression. L'Évolution Psychiatrique 86:3, pages 591-616.
Crossref
Crossref
Courtney Hutchison & Sara Bressi. (2020) Social Work and Psychedelic-Assisted Therapies: Practice Considerations for Breakthrough Treatments. Clinical Social Work Journal 49:3, pages 356-367.
Crossref
Crossref
L. Berkovitch, B. Roméo, L. Karila, R. Gaillard & A. Benyamina. (2021) Efficacité des psychédéliques en psychiatrie, une revue systématique. L'Encéphale 47:4, pages 376-387.
Crossref
Crossref
Sascha B. Thal, Stephen J. Bright, Jason M. Sharbanee, Tobias Wenge & Petra M. Skeffington. (2021) Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy. Frontiers in Psychology 12.
Crossref
Crossref
Displaying 200 of 309 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list